Katherine A Lyseng-Williamson

Summary

Affiliation: Adis International Inc
Country: USA

Publications

  1. doi request reprint Verigene® gram-positive blood culture nucleic acid test
    Lesley J Scott
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Mol Diagn Ther 17:117-22. 2013
  2. doi request reprint Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Mol Diagn Ther 17:57-62. 2013
  3. doi request reprint Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA
    Katherine A Lyseng-Williamson
    Adis, Auckland, New Zealand
    Mol Diagn Ther 16:317-22. 2012
  4. ncbi request reprint Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 22:1071-95. 2004
  5. doi request reprint Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 24:797-800. 2010
  6. ncbi request reprint Drotrecogin alfa (activated)
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 62:617-30; discussion 631-2. 2002
  7. ncbi request reprint Aripiprazole: in acute mania associated with bipolar I disorder
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:367-76; discussion 377-8. 2004
  8. ncbi request reprint Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 22:107-32. 2004
  9. doi request reprint Vemurafenib: a guide to its use in unresectable or metastatic melanoma
    Gillian M Keating
    Adis, 41 Centorian Drive Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 14:65-9. 2013
  10. ncbi request reprint Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    BioDrugs 27:525-31. 2013

Collaborators

Detail Information

Publications69

  1. doi request reprint Verigene® gram-positive blood culture nucleic acid test
    Lesley J Scott
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Mol Diagn Ther 17:117-22. 2013
    ..aureus and S. epidermidis organisms and vanA- or vanB-mediated vancomycin resistance in E. faecalis and E. faecium organisms...
  2. doi request reprint Erlotinib : a guide to its use in first-line treatment of non-small-cell lung cancer with epidermal growth factor-activating mutations
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    Mol Diagn Ther 17:57-62. 2013
    ....
  3. doi request reprint Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA
    Katherine A Lyseng-Williamson
    Adis, Auckland, New Zealand
    Mol Diagn Ther 16:317-22. 2012
    ..Therefore, cetuximab plus FOLFIRI is a useful biomarker-directed option in the first-line treatment of this patient population...
  4. ncbi request reprint Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 22:1071-95. 2004
    ..Etanercept may prevent or delay disability, which may produce reductions in nondrug costs that could help offset its acquisition cost...
  5. doi request reprint Pharmacoeconomic spotlight on varenicline as an aid to smoking cessation
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 24:797-800. 2010
    ....
  6. ncbi request reprint Drotrecogin alfa (activated)
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 62:617-30; discussion 631-2. 2002
    ..Of the 210 deaths in patients with severe sepsis treated with drotrecogin alfa (activated) 24 microg/kg/h in the efficacy trial, four deaths due to haemorrhage and one due to cerebral oedema were possibly related to the study drug...
  7. ncbi request reprint Aripiprazole: in acute mania associated with bipolar I disorder
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    CNS Drugs 18:367-76; discussion 377-8. 2004
    ..5 units), but generally significantly greater than with placebo in one of the 3-week trials. In the 12-week trial, changes from baseline were significantly smaller with aripiprazole than with haloperidol...
  8. ncbi request reprint Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 22:107-32. 2004
    ....
  9. doi request reprint Vemurafenib: a guide to its use in unresectable or metastatic melanoma
    Gillian M Keating
    Adis, 41 Centorian Drive Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 14:65-9. 2013
    ..Oral vemurafenib was generally well tolerated, with cutaneous adverse events among the most commonly occurring adverse events...
  10. ncbi request reprint Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    BioDrugs 27:525-31. 2013
    ..e. treatment interruption, dose reductions and/or permanent treatment discontinuation based on tolerability) and other precautions are followed. ..
  11. doi request reprint Dasatinib: a guide to its use in chronic myeloid leukemia in the EU
    Gillian M Keating
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    BioDrugs 27:275-9. 2013
    ..Thus, dasatinib is a highly effective, once-daily therapy for the first-line treatment of patients with chronic-phase CML and for the second-line treatment of imatinib-resistant or imatinib-intolerant CML...
  12. ncbi request reprint Clopidogrel: a pharmacoeconomic review of its use in patients with non-ST elevation acute coronary syndromes
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Pharmacoeconomics 24:709-26. 2006
    ..Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of clopidogrel plus aspirin for up to 1 year as a cost-effective treatment relative to aspirin alone in this patient population...
  13. doi request reprint Vandetanib: a guide to its use in advanced medullary thyroid cancer
    Gillian M Keating
    Adis, Auckland, New Zealand
    BioDrugs 26:431-5. 2012
    ..It has an acceptable tolerability profile in this patient population, although it does have the potential to prolong the corrected QT interval...
  14. doi request reprint Telavancin
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 69:2607-20. 2009
    ..aureus or other Gram-positive pathogens. Telavancin was generally well tolerated in patients with cSSSIs, with most adverse events being of mild or moderate severity...
  15. ncbi request reprint Lumiracoxib
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 64:2237-46; discussion 2247-8. 2004
    ..Lumiracoxib was not associated with an increase in cardiovascular events...
  16. doi request reprint Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Am J Clin Dermatol 14:61-4. 2013
    ..In an ongoing, noncomparative, phase II trial, oral vismodegib was effective in and had an acceptable tolerability profile in the treatment of patients with locally advanced or metastatic BCC...
  17. doi request reprint Spotlight on lenalidomide in relapsed or refractory multiple myeloma
    Lesley J Scott
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    BioDrugs 25:333-7. 2011
    ..Thus, combination therapy with lenalidomide plus dexamethasone provides a valuable option for the treatment of relapsed or refractory adult patients with multiple myeloma...
  18. doi request reprint Once-daily memantine: a guide to its use in moderate to severe Alzheimer's disease in the EU
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, Auckland, New Zealand
    Drugs Aging 30:51-8. 2013
    ..Memantine is well tolerated, with an adverse event profile that is similar to that with placebo...
  19. doi request reprint Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US
    Katherine A Lyseng-Williamson
    Adis, Auckland, New Zealand
    Am J Cardiovasc Drugs 12:207-16. 2012
    ..Limited pharmacoeconomic analyses suggest that prasugrel-based therapy is an economically attractive treatment strategy relative to clopidogrel-based therapy from a US healthcare payer perspective...
  20. doi request reprint Rasagiline: a guide to its use in Parkinson's disease
    Gillian M Keating
    Adis, Auckland, New Zealand
    CNS Drugs 26:781-5. 2012
    ..5 or 1 mg/day significantly reduces the total daily 'off' time. Rasagiline is generally well tolerated when administered as monotherapy or as adjunctive therapy...
  21. doi request reprint Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma
    Lesley J Scott
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:625-49. 2011
    ..Thus, combination therapy with lenalidomide plus dexamethasone provides a valuable option for the treatment of relapsed or refractory adult patients with multiple myeloma...
  22. doi request reprint Intravenous busulfan: a guide to its use as conditioning treatment before transplantation of haematopoietic progenitor cells
    Lesley J Scott
    Adis, Auckland, New Zealand
    Clin Drug Investig 32:641-8. 2012
    ..Intravenous busulfan was considered to have an acceptable tolerability profile...
  23. doi request reprint Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection
    Katherine A Lyseng-Williamson
    Adis, Auckland, New Zealand
    Clin Drug Investig 32:715-22. 2012
    ....
  24. ncbi request reprint Pegylated liposomal doxorubicin: a guide to its use in various malignancies
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    BioDrugs 27:533-40. 2013
    ..It has a favourable safety profile relative to conventional doxorubicin and other available chemotherapy agents. ..
  25. ncbi request reprint Canakinumab: a guide to its use in acute gouty arthritis flares
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754 Auckland, New Zealand
    BioDrugs 27:401-6. 2013
    ..Canakinumab has an acceptable tolerability profile in this difficult-to-treat population. The increased risk of infections and neutropenia associated with canakinumab treatment can be minimized by following the recommended precautions...
  26. ncbi request reprint Insulin lispro: a review of its use in the management of diabetes mellitus
    Dene Simpson
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 67:407-34. 2007
    ....
  27. doi request reprint Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer
    Lesley J Scott
    Adis, Auckland, New Zealand
    Drugs Aging 29:243-8. 2012
    ....
  28. ncbi request reprint Zoledronic acid : a review of its use in the management of bone metastases of malignancy
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:507-34. 2008
    ..Nevertheless, available clinical data indicate that zoledronic acid is an effective treatment option for the management of bone metastases of malignancy...
  29. ncbi request reprint Micronised purified flavonoid fraction: a review of its use in chronic venous insufficiency, venous ulcers and haemorrhoids
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 63:71-100. 2003
    ..MPFF may reduce the frequency, duration and/or intensity of symptoms of grade 1 or 2 acute internal haemorrhoids, and also the severity of the signs and symptoms of chronic haemorrhoids...
  30. ncbi request reprint Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 65:413-32. 2005
    ..Tenofovir DF provides a simple and convenient once-daily dosage regimen, and is generally well tolerated and able to produce sustained suppression of viral replication...
  31. ncbi request reprint Pranlukast: a review of its use in the management of asthma
    Susan J Keam
    Adis International Limited, Auckland, New Zealand
    Drugs 63:991-1019. 2003
    ..Although Churg-Strauss syndrome has been noted in pranlukast recipients, a direct causal relationship is unlikely...
  32. ncbi request reprint Adalimumab: in Crohn's disease
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand
    BioDrugs 21:125-32; discussion 133-4. 2007
    ..In general, the tolerability profile of adalimumab in patients with Crohn's disease was similar to that in patients with rheumatoid arthritis or other approved indications...
  33. doi request reprint Fentanyl pectin nasal spray: in breakthrough pain in opioid-tolerant adults with cancer
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    CNS Drugs 25:511-22. 2011
    ..Most patients were satisfied or very satisfied with the ease of use and convenience of the nasal spray. Fentanyl pectin nasal spray 100-800 μg was generally well tolerated and was not associated with nasal tolerability problems...
  34. doi request reprint Posaconazole: a pharmacoeconomic review of its use in the prophylaxis of invasive fungal disease in immunocompromised hosts
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 29:251-68. 2011
    ....
  35. ncbi request reprint Docetaxel: a review of its use in metastatic breast cancer
    Katherine A Lyseng-Williamson
    Adis International Limited, Auckland, New Zealand
    Drugs 65:2513-31. 2005
    ..Docetaxel, therefore, is an effective option in the treatment of patients with metastatic breast cancer after failure of prior chemotherapy...
  36. ncbi request reprint Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease
    Greg L Plosker
    Adis International Limited, Auckland, New Zealand
    Pharmacoeconomics 23:193-206. 2005
    ....
  37. ncbi request reprint Tolcapone: a review of its use in the management of Parkinson's disease
    Gillian M Keating
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    CNS Drugs 19:165-84. 2005
    ..Thus, tolcapone is a useful option in patients with fluctuating Parkinson's disease who are receiving levodopa/DDCI and are not responding to, or are not candidates for, other adjunctive treatments...
  38. doi request reprint Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation
    Gillian M Keating
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 28:231-54. 2010
    ....
  39. doi request reprint Fondaparinux: a pharmacoeconomic review of its use in the management of non-ST-segment elevation acute coronary syndrome
    Kate McKeage
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 28:687-98. 2010
    ..This cost advantage primarily reflects the lower rate of bleeding with fondaparinux than with enoxaparin and the lower rate of mortality and morbidity over the long term...
  40. ncbi request reprint Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Pharmacoeconomics 20:919-42. 2002
    ..From a societal perspective, the caregiver burden of caring for a patient with Alzheimer's disease in the community may be decreased and the time that patients have without severe disease may be prolonged...
  41. ncbi request reprint Extended-release methylphenidate (Ritalin LA)
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Drugs 62:2251-9; discussion 2260-1. 2002
    ..In clinical trials, the safety and tolerability profiles of extended-release methylphenidate were consistent with that of the immediate-release formulation...
  42. doi request reprint Loteprednol etabonate ophthalmic gel 0.5%: a review of its use in post-operative inflammation and pain following ocular surgery
    Katherine A Lyseng-Williamson
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand
    Drugs 73:949-58. 2013
    ..It provides uniform dosing of a topical ophthalmic corticosteroid that has been demonstrated to be effective and well-tolerated in the treatment of ocular inflammation...
  43. ncbi request reprint Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes
    Dene Simpson
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 66:2397-416. 2006
    ..Convenient patient-initiated single-day (for recurrent genital herpes) and single-dose (for orolabial herpes) dosage regimens may contribute to treatment compliance, patient acceptability and subsequent treatment outcomes...
  44. doi request reprint Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Am J Cardiovasc Drugs 12:49-56. 2012
    ..Dual treatment with ezetimibe/simvastatin is more effective than monotherapy with an HMG-CoA reductase inhibitor (statin), and the addition of ezetimibe to current statin therapy is more effective than doubling the statin dose...
  45. ncbi request reprint Intravenous busulfan: in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation
    Sheridan M Hoy
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Paediatr Drugs 9:271-8. 2007
    ..Unlike oral busulfan, intravenous busulfan does not appear to be associated with severe HVOD or death due to organ toxicity...
  46. doi request reprint A/H5N1 prepandemic influenza vaccine (Vepacel®): a guide to its use
    Gillian M Keating
    Adis, Auckland, New Zealand
    BioDrugs 26:425-30. 2012
    ..In general, adverse events observed in clinical immunogenicity studies with a whole virions H5N1 vaccine (A/Vietnam/1203/2004) were similar to those reported with non-adjuvanted, inactivated, split virion seasonal influenza vaccines...
  47. ncbi request reprint Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma
    Katherine A Lyseng-Williamson
    Adis International Limited, Mairangi Bay, Auckland, New Zealand
    Pharmacoeconomics 21:951-89. 2003
    ....
  48. doi request reprint Erlotinib: a pharmacoeconomic review of its use in advanced non-small cell lung cancer
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 28:75-92. 2010
    ..Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of erlotinib as a cost-saving treatment relative to chemotherapy with docetaxel or pemetrexed in this patient population...
  49. doi request reprint Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia
    Tracy S Harrison
    Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand
    BioDrugs 27:69-74. 2013
    ..At a dose of 2.25 mg/m(2) once weekly, this formulation was associated with an overall response rate of 35 % in adults with Philadelphia chromosome-negative relapsed or refractory disease. There were no new or unexpected toxicities...
  50. ncbi request reprint Imatinib: in relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukaemia
    Sarah A Cross
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:2645-54. 2007
    ..5% and 44.8%. * Although adverse events were frequent among relapsed or refractory Ph+ ALL patients treated with imatinib, the majority of non-haematological adverse events were mild or moderate in severity...
  51. ncbi request reprint Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 25:1031-53. 2007
    ..Although a clear pattern is not evident from available data, intuitively, the value of atorvastatin would be expected to increase with the patient's risk for serious cardiovascular events...
  52. doi request reprint Zoledronic acid: a review of its use in breast cancer
    Katherine A Lyseng-Williamson
    Wolters Kluwer Health, Adis, Auckland, New Zealand
    Drugs 68:2661-82. 2008
    ....
  53. ncbi request reprint Trastuzumab: a pharmacoeconomic review of its use in early breast cancer
    Kate McKeage
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Pharmacoeconomics 26:699-719. 2008
    ..Available pharmacoeconomic data from several countries, despite some inherent limitations, support the use of adjuvant trastuzumab for 1 year as a cost-effective treatment relative to chemotherapy alone in this patient population...
  54. ncbi request reprint Etanercept: a review of its use in the management of rheumatoid arthritis
    Sohita Dhillon
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 67:1211-41. 2007
    ..Nevertheless, extensive clinical experience indicates that etanercept is a valuable treatment option in adult patients with long-standing moderate to severe active rheumatoid arthritis and an emerging option in those with early disease...
  55. ncbi request reprint Raltegravir
    Jamie D Croxtall
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:131-8. 2008
    ..Raltegravir therapy was well tolerated overall. The incidence of mild to moderate adverse events was similar in the raltegravir and placebo arms of the two randomized trials...
  56. ncbi request reprint Moxonidine: a review of its use in essential hypertension
    Caroline Fenton
    Adis International Limited, Auckland, New Zealand
    Drugs 66:477-96. 2006
    ..Thus, moxonidine is a good option in the treatment of patients with mild to moderate hypertension, particularly as adjunctive therapy in patients with the metabolic syndrome...
  57. doi request reprint Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria
    Gillian M Keating
    Adis, Auckland, New Zealand
    BioDrugs 26:125-30. 2012
    ..Eculizumab is generally well tolerated in patients with PNH, although the risk of Neisseria meningitidis infection is increased with eculizumab, meaning that patients must be vaccinated...
  58. doi request reprint OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine
    Katherine A Lyseng-Williamson
    Adis, Auckland, New Zealand
    CNS Drugs 26:717-23. 2012
    ..OnaBoNTA was generally well tolerated in these trials, with an adverse event profile that was consistent with that of the neurotoxin when injected into head and neck muscles...
  59. doi request reprint Dexmedetomidine: a guide to its use for sedation in the US
    Gillian M Keating
    Adis, Auckland, New Zealand
    Clin Drug Investig 32:561-7. 2012
    ..Although the utilization of dexmedetomidine is associated with hypotension and bradycardia, both usually resolve without intervention...
  60. doi request reprint Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain
    Greg L Plosker
    Adis, Auckland, New Zealand
    CNS Drugs 26:367-73. 2012
    ..Transdermal buprenorphine has also shown analgesic efficacy in patients with chronic non-malignant pain of various causes...
  61. doi request reprint Bazedoxifene: a guide to its use in postmenopausal osteoporosis
    Gillian M Keating
    Adis, Auckland, New Zealand
    Drugs Aging 29:329-34. 2012
    ..It also appears to reduce the risk of nonvertebral fractures in high-risk patients. Bazedoxifene is generally well tolerated and does not appear to have detrimental effects on endometrial or breast tissue...
  62. ncbi request reprint Nelarabine
    Mark Sanford
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:439-47. 2008
    ..Treatment-emergent adverse events were common, but non-haematological events were mostly of mild or moderate severity. Neurological events, which may be severe and irreversible, were the most likely adverse events to limit treatment...
  63. ncbi request reprint Aripiprazole: in major depressive disorder
    Juliane Weber
    Wolters Kluwer Health Adis, Auckland, New Zealand
    CNS Drugs 22:807-13. 2008
    ..In these two pivotal trials, adjunctive aripiprazole 2-20 mg/day was generally well tolerated, with most treatment-emergent adverse events being of mild to moderate severity...
  64. doi request reprint Subcutaneous recombinant interferon-β-1a (Rebif®): a review of its use in the treatment of relapsing multiple sclerosis
    Mark Sanford
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs 71:1865-91. 2011
    ..Overall, SC IFNβ-1a has a favourable risk-benefit ratio and is a valuable first-line treatment option for patients with relapsing MS...
  65. doi request reprint Bivalirudin: a pharmacoeconomic profile of its use in patients with acute coronary syndromes
    Katherine A Lyseng-Williamson
    Adis, Wolters Kluwer Business, Auckland, New Zealand
    Pharmacoeconomics 29:343-59. 2011
    ....
  66. ncbi request reprint Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults
    Kate McKeage
    Wolters Kluwer Health Adis, Auckland, New Zealand
    Drugs 68:1571-607. 2008
    ..pylori eradication remains undisputed, and the data support its use for the first-line treatment of NSAID-associated gastric ulcer disease and Zollinger-Ellison syndrome...
  67. ncbi request reprint Clopidogrel: a review of its use in the prevention of thrombosis
    Greg L Plosker
    Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
    Drugs 67:613-46. 2007
    ..In addition, treatment guidelines from the US and Europe acknowledge the importance of clopidogrel in contemporary cardiovascular medicine...
  68. pmc Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation
    Katherine A Lyseng-Williamson
    Adis, a Wolters Kluwer Business, Auckland, New Zealand
    Drugs R D 10:253-60. 2010
    ....
  69. ncbi request reprint Oromucosal midazolam: a guide to its use in paediatric patients with prolonged acute convulsive seizures
    Lesley J Scott
    Adis, Auckland, New Zealand
    CNS Drugs 26:893-7. 2012
    ..It has several advantages over rectal diazepam, the previous gold standard of treatment, such as having a more convenient and socially acceptable administration route...